Cargando…

Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients

Detalles Bibliográficos
Autores principales:	Scott, Shane J., Stolshek, Bradley S., Fridman, Moshe, Delgado, David J., Link, Brian K., Chrischilles, Elizabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Cea
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437157/ https://www.ncbi.nlm.nih.gov/pubmed/14613340 http://dx.doi.org/10.18553/jmcp.2003.9.s2.15

Ejemplares similares

Continuing Education
por: Chrischilles, Elizabeth A., et al.
Publicado: (2003)

Assessing Resource Use in Oncology Patients
por: Semroc, Georgette N., et al.
Publicado: (2003)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis
por: Li, Edward, et al.
Publicado: (2021)

Prevention of febrile neutropenia: use of prophylactic antibiotics
por: Cullen, M, et al.
Publicado: (2009)

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
por: Aapro, M., et al.
Publicado: (2016)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Statistical Issues with the Analysis of Nonrandomized Studies in Comparative Effectiveness Research
por: Alemayehu, Demissie, et al.
Publicado: (2011)

Overview of Pharmacologic Therapy for the Treatment of Dyslipidemia
por: Lipsy, Robert J.
Publicado: (2003)

Introduction
por: Lipsy, Robert J.
Publicado: (2003)

Developing a Collaborative Study Protocol for Combining Payer-Specific Data and Clinical Trials for CER
por: Sanchez, Robert J., et al.
Publicado: (2011)

Successful HIV Treatment
por: Cohen, Calvin J.
Publicado: (2006)

Introduction
por: Sax, Michael J.
Publicado: (2005)

Value-Based Benefit Design: Using a Predictive Modeling Approach to Improve Compliance
por: Mahoney, John J.
Publicado: (2008)

Essential Steps and Practical Applications for Database Studies
por: Sax, Michael J.
Publicado: (2005)

Disease Progression and the Application of Evidence-Based Treatment Guidelines Diagnose It Early: A Case for Screening and Appropriate Management
por: Manley, Harold J.
Publicado: (2007)

Evidence Based Medicine Health Care's Next Holy War
por: Kleinke, J.D.
Publicado: (2005)

Introduction
por: Cziraky, Mark J.
Publicado: (2008)

Not Getting to Goal: The Clinical Costs of Noncompliance
por: Ansell, Benjamin J.
Publicado: (2008)

Preview Overview
por: Lipsy, Robert J.
Publicado: (2004)

The Importance and Impact of Evidence Based medicine
por: Lewis, Sonya J., et al.
Publicado: (2004)

Introduction
por: Mullins, C. Daniel, et al.
Publicado: (2011)

“Ten Commandments” for Conducting Comparative Effectiveness Research Using “Real-World Data”
por: Willke, Richard J., et al.
Publicado: (2011)

Considerations on the Use of Patient-Reported Outcomes in Comparative Effectiveness Research
por: Alemayehu, Demissie, et al.
Publicado: (2011)

Introduction
por: kleinke, J.D., et al.
Publicado: (2005)

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
por: Foley, John F., et al.
Publicado: (2013)

Part1 How the Emergence of Innovative Biologic Agents Impacts Benefit Design, Utilization, and Provider Relations
por: Lipsy, Robert J., et al.
Publicado: (2004)

Continuing Education
por: Lipsy, Robert J., et al.
Publicado: (2004)

Continuing Education
por: Carter, Barry L., et al.
Publicado: (2004)

Health Information Technology—Results From a Roundtable Discussion
por: Balfour, Donald C., et al.
Publicado: (2009)

The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
por: Balfour III, Donald C., et al.
Publicado: (2009)

Pharmacoeconomics and Considerations for Injectable Products: Focus on Colony-Stimulating Factors
por: Chrischilles, Elizabeth A., et al.
Publicado: (2003)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ee7kgsc6i79q01brrqdf3celaa